



## Appraisal

## Clinimetrics: Modified Rankin Scale (mRS)

The modified Rankin Scale (mRS) is a single-item, global outcome rating scale that was developed to measure the degree of disability or dependence in the daily activities of people who have suffered from stroke or other neurological disorders.<sup>1</sup> The mRS is the most commonly used Patient Reported Outcome Measure (PROM) for acute stroke trials.<sup>2</sup> It is currently cited within the Australian Clinical Practice Guidelines for its use regarding long-term care.<sup>3</sup> As well as being the consensus-based core recommendations from the stroke recovery and rehabilitation roundtable,<sup>4</sup> it is also included in the core outcome set for patients following cardiac arrest.<sup>5</sup> The mRS was originally introduced in 1957 and was later modified in the 1980s as part of the United Kingdom Transient Ischaemic Attack (UK-TIA) trial. The modification was to accommodate language disorders and cognitive difficulties.<sup>1</sup> The mRS has a range between 0 and 6, where a score of 0 is 'no symptoms at all' and a score of 6 is 'dead'; there are no subscales. The mRS is free and does not require any specialised equipment to administer.<sup>2</sup> A modified Rankin Scale Structured Interview (mRS-SI) takes 5 to 15 minutes to complete.<sup>6</sup> A simplified modified Rankin questionnaire (smRSq) can also be used and takes 1.67 minutes; it can be used by multidisciplinary healthcare professionals, from junior staff to consultants.<sup>7</sup> The National Institute of Health Stroke Scales (NIHSS) has validated translations of the scale to English and 11 other languages, including Mandarin and Spanish.<sup>8</sup>

The mRS has been shown to have acceptable inter-rater reliability, and excellent test-retest and intra-rater reliability. The inter-rater reliability was found to be higher when using the mRS-SI compared with the mRS (k 0.78 versus 0.56).<sup>9</sup> Furthermore, the mRS has good criterion validity, as it has a strong correlation with multiple scales that reflect the current gold standard of scoring impairment, disability and/or handicap. For instance, excellent correlations were displayed between the Barthel Index with  $r = -0.81$ , Frenchay Activities Index (FAI) with  $r = -0.80$  and EuroQol-5 Dimension with  $r = 0.68$ .<sup>10</sup> The mRS construct validity has also been confirmed by multiple studies. The relationship between severity of disability and mRS score has been defined in numerous investigations as a poor outcome with  $mRS > 2$  or  $> 3$ .<sup>9</sup> The mRS is less sensitive to changes in disability compared with the Barthel Index;<sup>8</sup> as a result, stroke trials using mRS as their PROM may fail to detect a clinically significant difference between stroke treatments. It is recommended that a 'favourable outcome' be defined as an improvement in grade, rather than using a dichotomisation process.<sup>11</sup> However, the mRS has a stronger performance than the Barthel Index at the floor and ceiling of the scale. This is because the

mRS is a more global scale that skips smaller, incremental steps of improvement in rehabilitation.<sup>8</sup>

One of the key strengths of the mRS is its reference to the patient's function prior to their neurological deficit. This makes the mRS a superior prognosticator to scales that do not refer to previous activities;<sup>1</sup> for example: a study conducted by the University of Glasgow concluded that the pre-stroke mRS is a moderately valid measure of pre-stroke disability and a robust predictor of poststroke prognosis.<sup>12</sup> This helps physiotherapists and other members of the healthcare team to plan for service delivery and ongoing care. In addition, a study conducted in the Interuniversity Centre for Health Economics Research used the mRS as a determinant of direct medical costs after stroke.<sup>13</sup> The researchers found that the mRS rating of the level of disability was a major determinant of resource use, irrespective of age, gender, atrial fibrillation and vascular risk factors.

In conclusion, the mRS has shown true value in being a global scale that reflects the interaction with and adaptation to a person's disability, particularly as it refers to the functioning prior to the disabling event. While the inter-rater reliability can be enhanced using a structured interview, there are concerns about its responsiveness. However, its strengths in content, construct, criterion validity and intra-rater reliability outweigh its weaknesses.

**Provenance:** Invited. Not peer reviewed

**Hammazah Haggag and Carol Hodgson**

*School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia*

### References

1. Van Swieten J, et al. *Stroke*. 1988;19:604–607.
2. Broderick JP, et al. *Stroke*. 2017;48:2007–2012.
3. Stroke Foundation. *Clinical Guidelines for Stroke Management*. 2017:chap 8. <https://informme.org.au/guidelines/clinical-guidelines-for-stroke-management>
4. Kwakkel G, et al. *Int J Stroke*. 2017;12:451–461.
5. Haywood K, et al. *Circulation*. 2018;137:e783–e801.
6. Wilson JL, et al. *Stroke*. 2002;33:2243–2246.
7. Bruno A, et al. *Stroke*. 2010;41:1048–1050.
8. Lees KR, et al. *Stroke*. 2012;43:1163–1170.
9. Banks JL, et al. *Stroke*. 2007;38:1091–1096.
10. Cup EHC, et al. *Clin Rehabil*. 2003;17:402–409.
11. New PW, et al. *Neuroepidemiology*. 2006;26:4–15.
12. Quinn TJ, et al. *Front Neurol*. 2017;8:275.
13. Dewilde S, et al. *Int J Stroke*. 2017;12:392–400.